Press Releases Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

End-of-day quote Buenos Aires S.E. Other stock markets 03:30:00 01/07/2024 am IST			5-day change	1st Jan Change
24,177 ^ARS	+4.13%		+3.76%	+22.29%

01/07	HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	MT
01/07	HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gilead Benefit Helps Employees Navigate Cancer Care	01/07	AQ
Gilead small molecule demonstrates strong capability for HIV prevention	21/06	AQ
Gilead Sciences : Access Planning in High Incidence, Resource Limited Countries for Lenacapavir for HIV Prevention	21/06	PU
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention	20/06	BU
Gilead and Kite Pharma Celebrates Pride Month	19/06	AQ
New Kite Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit from Earlier Lines of Treatment	17/06	AQ
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment	14/06	BU
Namibian First Ladies Call for New HIV Medicine	13/06	AQ
Combination therapy may hold potential for severe viral hepatitis	06/06	AQ
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	06/06	AQ
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	06/06	BU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	05/06	AQ
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	05/06	BU
Gilead Sciences : Statement on Agreement in Principle to Resolve Federal TDF Litigation	04/06	PU
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	03/06	BU
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma	03/06	BU
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024	31/05	BU
Gilead Provides Update on Phase 3 TROPiCS-04 Study	31/05	BU
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies against Novel Targets and Target Pairs	29/05	AQ
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024	22/05	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

Press Releases

Filters